Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A.
Holstein K, Albisetti M, Bidlingmaier C, Halimeh S, Heine S, Klamroth R, Königs C, Kurnik K, Male C, Oldenburg J, Streif W, Wermes C, Escuriola-Ettingshausen C; ‘Ständige Kommission Hämophilie’ (Haemophilia board) of the German, Swiss Austrian Society for Thrombosis Haemostasis Research (GTH). Holstein K, et al. Among authors: oldenburg j. Hamostaseologie. 2020 Dec;40(5):561-571. doi: 10.1055/a-1127-6476. Epub 2020 Jun 25. Hamostaseologie. 2020. PMID: 32588417 Review.
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Whelan SF, et al. Among authors: oldenburg j. Blood. 2013 Feb 7;121(6):1039-48. doi: 10.1182/blood-2012-07-444877. Epub 2012 Dec 12. Blood. 2013. PMID: 23243272 Free article.
Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
Pollmann H, Klamroth R, Vidovic N, Kriukov AY, Epstein J, Abraham I, Spotts G, Oldenburg J. Pollmann H, et al. Among authors: oldenburg j. Ann Hematol. 2013 May;92(5):689-98. doi: 10.1007/s00277-013-1678-4. Epub 2013 Jan 17. Ann Hematol. 2013. PMID: 23324986
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Eckhardt CL, et al. Among authors: oldenburg j. Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Blood. 2013. PMID: 23926300 Free article.
[Hamburg Hemophilia Symposium 2012].
Oldenburg J, Kurnik K. Oldenburg J, et al. Hamostaseologie. 2013;33 Suppl 1:S1. Hamostaseologie. 2013. PMID: 24344444 German. No abstract available.
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.
Hofbauer CJ, Whelan SF, Hirschler M, Allacher P, Horling FM, Lawo JP, Oldenburg J, Tiede A, Male C, Windyga J, Greinacher A, Knöbl PN, Schrenk G, Koehn J, Scheiflinger F, Reipert BM. Hofbauer CJ, et al. Among authors: oldenburg j. Blood. 2015 Feb 12;125(7):1180-8. doi: 10.1182/blood-2014-09-598268. Epub 2014 Dec 16. Blood. 2015. PMID: 25515962 Free article.
763 results